Investigation of vitamin and mineral tablets and capsules on the Canadian market

  • Author(s) / Creator(s)
  • Abstract: PURPOSE: The goal of this study was to investigate the disintegrating properties of tablets and capsules containing minerals and vitamins commercially available on the Canadian market and to review their label information. METHODS: The labels were examined for product-related information. The first disintegration test stage was performed using Simulated Intestinal Fluid (SIF) pH 6.8 for 20 minutes. Products which did not disintegrate were further investigated using USP disintegration conditions for dietary supplements. RESULTS: The provided label information is difficult to understand and in some cases pseudo-scientific. Thirty out of thirty-nine tablets and six out of ten capsules had a Drug Identification Number ( DIN). Twenty-one of thirty-nine tablets and four out of the ten capsules did not disintegrate within 20 minutes. Using the USP disintegration conditions for dietary supplements nine tablet products did not fully disintegrate but all capsules passed the test. None of the three \"time-released\" products disintegrated under the applied conditions. CONCLUSIONS: Industry should follow already existing label recommendations more closely to allow the consumers to make an informed decision on their products by providing only essential information rather than using pseudo-scientific terms. The results of the disintegration study indicated that disintegration, one of the most basic quality control parameters, is still a concern for dietary supplements.

  • Date created
    2006
  • Subjects / Keywords
  • Type of Item
    Article (Published)
  • DOI
    https://doi.org/10.7939/R3HD7NV1V
  • License
    This work is made available under the terms of the Creative Commons Attribution - Share Alike 3.0 Unported license, http://creativecommons.org/licenses/by-sa/3.0/.
  • Language
  • Citation for previous publication
    • Löbenberg, R. and Steinke, W. (2006). Investigation of vitamin and mineral tablets and capsules on the Canadian market. J Pharm Pharm Sci, 9(1), 40-49.